A Phase 1/2a Study to Evaluate Single Intraarticular Injections of 3 Dose Levels of SYN321 and Placebo in Patients With Symptomatic Knee Osteoarthritis
NCT ID: NCT06989645
Last Updated: 2025-09-03
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
36 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-08-19
Study Completion Date
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a, phase 1/2a trial, to assess the safety, tolerability, systemic exposure as well as preliminary efficacy following a single intra-articular injection of 3 dose levels of SYN321 in patients with symptomatic knee osteoarthritis (KOA).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial of a Single Delivery of SB-061 in Osteoarthritis of the Knee
NCT03231280
Osteoarthritis
COMPLETED
PHASE1/PHASE2
Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part II
NCT01598415
Knee Osteoarthritis
COMPLETED
PHASE2
Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee
NCT05419856
Knee Osteoarthritis
COMPLETED
PHASE1
A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain
NCT00394563
Osteoarthritis
COMPLETED
PHASE2
Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the Knee
NCT00653432
Osteoarthritis
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will receive a single intra-articular injection of SYN321 or placebo. 4 sequential cohorts are planned. The fourth cohort will repeat one of the previously 3 administered dose levels. The first 2 participants in each cohort will be dosed in a sentinel fashion. The participants will be followed for 56 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Osteoarthritis of Knee
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
SEQUENTIAL
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
DOUBLE
Participants
Investigators
Double blind-trial
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SYN321, dose level 1
Cohort 1: 6 participants recieves SYN321.
Group Type
ACTIVE_COMPARATOR
SYN321
Intervention Type
DRUG
Intra-articular
SYN321, dose level 2
Cohort 2: 6 participants recieves SYN321.
Group Type
ACTIVE_COMPARATOR
SYN321
Intervention Type
DRUG
Intra-articular
SYN321, dose level 3
Cohort 3: 6 participants recieves SYN321.
Group Type
ACTIVE_COMPARATOR
SYN321
Intervention Type
DRUG
Intra-articular
SYN321, dose level 1,2 or 3
Cohort 4: 6 participants recieves SYN321.
Group Type
ACTIVE_COMPARATOR
SYN321
Intervention Type
DRUG
Intra-articular
Placebo
Placebo: 2 participants each from cohort 1, 2 and 3, and 6 participants from cohort 4 receive placebo.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Intra-articular
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SYN321
Intra-articular
Intervention Type
DRUG
Placebo
Intra-articular
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
NaCl 9 mg/mL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Willing and able to give electronically informed consent for participation in the trial and willing and able to participate in all procedures and follow-up evaluations necessary to complete the trial.
2. Male or female patient clinically diagnosed with KOA, no later than 3 months prior to Visit 1. The KOA diagnosis should be confirmed in the patient's medical record.
3. Dominant pain in one knee due to KOA with weight bearing pain between 4 and 8 inclusive on the NRS scale (0-10) at the time of inclusion (checked at screening \[Visit 1\] and confirmed at Visit 2, pain during the last 7 days).
4. Age 40 to 79 years, inclusive at the time of Visit 1.
5. Body mass index (BMI) ≥ 18.5 and \< 35.0 kg/m2.
6. Patients without abnormal clinically significant medical history, physical findings, vital signs, hypotension, cardiovascular disease, ECG, and laboratory values at the time of the screening visit, as judged by the Investigator. (Discussion is encouraged between the Investigator and the Medical Monitor regarding the clinical relevance of any abnormal laboratory value during the pre-dose period.)
7. Patient is willing to discontinue all pain medication (COX-2 inhibitors, NSAIDs, and opioid analgesics) at least 10 days before trial drug administration (prior to Day 1) and for the trial duration. Paracetamol will be allowed as rescue medication up to max 4000 mg/day (except for 24 hours prior to visit to the trial site).
8. Patient agrees not to take additional knee symptom-modifying drugs (e.g., glucosamine, collagen, HA) at least 10 days before trial drug administration (prior to Day 1) and for the trial duration.
9. WOCBP must practice abstinence heterosexual intercourse (only allowed when this is the preferred and usual lifestyle of the patient) or agree to use a highly effective method of contraception with a failure rate of \< 1 % to prevent pregnancy from that least 2 weeks prior to the administration of IMP to 4 weeks after the last administration of IMP. In addition, any male partner of a female patient must, unless he has undergone vasectomy, agree to use a condom from the first administration of IMP until 4 weeks after the last administration of IMP.
The following are considered highly effective methods of contraception:
* combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal),
* progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable),
* intrauterine device \[IUD\]or intrauterine hormone-releasing system \[IUS\]). WOCBP must refrain from donating eggs from the first IMP administration until 3 months after the last IMP administration.
Women of non-childbearing potential are pre-menopausal females who have undergone any of the following surgical procedures; hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, or who are post-menopausal defined as 12 months of amenorrhea (in questionable cases a blood sample with detection of follicle stimulating hormone \[FSH\] \>25 IU/L is confirmatory).
Male patients must be willing to use condom or be vasectomized or practice sexual abstinence from heterosexual intercourse (only allowed when this is the preferred and usual lifestyle of the patient) to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the first administration of IMP until 3 months after the last administration of IMP. Any female partner of a non-vasectomized male patient who is of childbearing potential must use contraceptive methods with a failure rate of \< 1% to prevent pregnancy (see above) from at least 2 weeks prior to the first administration of IMP to 4 weeks after the last administration of IMP.
10. Patients without contraindications for treatment with diclofenac.
2. Male or female patient clinically diagnosed with KOA, no later than 3 months prior to Visit 1. The KOA diagnosis should be confirmed in the patient's medical record.
3. Dominant pain in one knee due to KOA with weight bearing pain between 4 and 8 inclusive on the NRS scale (0-10) at the time of inclusion (checked at screening \[Visit 1\] and confirmed at Visit 2, pain during the last 7 days).
4. Age 40 to 79 years, inclusive at the time of Visit 1.
5. Body mass index (BMI) ≥ 18.5 and \< 35.0 kg/m2.
6. Patients without abnormal clinically significant medical history, physical findings, vital signs, hypotension, cardiovascular disease, ECG, and laboratory values at the time of the screening visit, as judged by the Investigator. (Discussion is encouraged between the Investigator and the Medical Monitor regarding the clinical relevance of any abnormal laboratory value during the pre-dose period.)
7. Patient is willing to discontinue all pain medication (COX-2 inhibitors, NSAIDs, and opioid analgesics) at least 10 days before trial drug administration (prior to Day 1) and for the trial duration. Paracetamol will be allowed as rescue medication up to max 4000 mg/day (except for 24 hours prior to visit to the trial site).
8. Patient agrees not to take additional knee symptom-modifying drugs (e.g., glucosamine, collagen, HA) at least 10 days before trial drug administration (prior to Day 1) and for the trial duration.
9. WOCBP must practice abstinence heterosexual intercourse (only allowed when this is the preferred and usual lifestyle of the patient) or agree to use a highly effective method of contraception with a failure rate of \< 1 % to prevent pregnancy from that least 2 weeks prior to the administration of IMP to 4 weeks after the last administration of IMP. In addition, any male partner of a female patient must, unless he has undergone vasectomy, agree to use a condom from the first administration of IMP until 4 weeks after the last administration of IMP.
The following are considered highly effective methods of contraception:
* combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal),
* progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable),
* intrauterine device \[IUD\]or intrauterine hormone-releasing system \[IUS\]). WOCBP must refrain from donating eggs from the first IMP administration until 3 months after the last IMP administration.
Women of non-childbearing potential are pre-menopausal females who have undergone any of the following surgical procedures; hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, or who are post-menopausal defined as 12 months of amenorrhea (in questionable cases a blood sample with detection of follicle stimulating hormone \[FSH\] \>25 IU/L is confirmatory).
Male patients must be willing to use condom or be vasectomized or practice sexual abstinence from heterosexual intercourse (only allowed when this is the preferred and usual lifestyle of the patient) to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the first administration of IMP until 3 months after the last administration of IMP. Any female partner of a non-vasectomized male patient who is of childbearing potential must use contraceptive methods with a failure rate of \< 1% to prevent pregnancy (see above) from at least 2 weeks prior to the first administration of IMP to 4 weeks after the last administration of IMP.
10. Patients without contraindications for treatment with diclofenac.
Exclusion Criteria
1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the trial, or influence the results or the patient's ability to participate in the trial.
2. Previous IA fracture of the knee.
3. Patient has rheumatoid arthritis, psoriatic arthritis, or has been diagnosed with any other disorders that is the primary source of their knee pain, including but not limited to: osteonecrosis, radiculopathy, bursitis, tendinitis, tumor, cancer.
4. IA injections of steroids or HA or other invasive procedure (e.g., arthroscopy, arthrography, surgery) in the knee within 3 months prior to screening.
5. Conditions or medications that could confound the assessment of pain, as judged by the Investigator.
6. Conditions that could be adversely affected by an IA injection (e.g., eczema, skin infection, high bleeding risk etc.), as judged by the Investigator.
7. Any clinically significant illness (except KOA), medical/surgical procedure, or trauma within 4 weeks of the administration of IMP.
8. Malignancy within the past 5 years, with the exception of in situ removal of basal cell carcinoma.
9. Any planned major surgery within the duration of the trial.
10. Patients who are pregnant, currently breastfeeding, or intend to become pregnant during the course of the trial.
11. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibodies and/or human immunodeficiency virus (HIV).
12. After 10 minutes supine rest at the time of screening, any vital signs outside the following ranges:
* Systolic blood pressure (BP): \<90 or \>160 mmHg, or
* Diastolic blood pressure \<50 or \>95 mmHg, or
* Pulse \<40 or \>90 bpm
13. Prolonged QTcF (\> 450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the Investigator.
14. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to SYN321, including disinfectants and adhesives or hypersensitivity to acetylsalicylic acid.
15. History of asthma, angioedema, urticaria or acute rhinitis induced by NSAID, including acetylsalicylic acid.
16. Regular use of any prescribed or non-prescribed medications, including but not limited to antacids, analgesics, herbal remedies, vitamins and minerals, within 10 days prior to the first administration of IMP, as well as nasal decongestants without cortisone, antihistamine, or anticholinergics for a maximum of 10 days, at the discretion of the Investigator.
17. Patient has taken pain medication or has received pain medicine other than paracetamol for conditions unrelated to KOA of the index knee within 10 days prior to the injection.
18. Planned treatment or treatment with another investigational drug within 3 months prior to Day 1. Patients consented and screened but not dosed in previous phase 1 studies will not be excluded.
19. Current smokers or users of nicotine products. Irregular use of nicotine (e.g., smoking, snuffing, chewing tobacco) less than 3 times/week before the screening visit will be allowed.
20. Positive screen for drugs of abuse or alcohol at screening. Positive results that are expected given the patient's medical history and prescribed medications can be disregarded as judged by the Investigator.
21. History of or current alcohol abuse or excessive intake of alcohol, as judged by the Investigator.
22. History of or current drug abuse, as judged by the Investigator.
23. History of or current use of anabolic steroids, as judged by the Investigator.
24. Plasma donation within 1 month of screening or blood donation (or corresponding blood loss) during the last 3 months prior to screening.
25. The Investigator considers the patient unlikely to comply with trial procedures, restrictions, and requirements.
2. Previous IA fracture of the knee.
3. Patient has rheumatoid arthritis, psoriatic arthritis, or has been diagnosed with any other disorders that is the primary source of their knee pain, including but not limited to: osteonecrosis, radiculopathy, bursitis, tendinitis, tumor, cancer.
4. IA injections of steroids or HA or other invasive procedure (e.g., arthroscopy, arthrography, surgery) in the knee within 3 months prior to screening.
5. Conditions or medications that could confound the assessment of pain, as judged by the Investigator.
6. Conditions that could be adversely affected by an IA injection (e.g., eczema, skin infection, high bleeding risk etc.), as judged by the Investigator.
7. Any clinically significant illness (except KOA), medical/surgical procedure, or trauma within 4 weeks of the administration of IMP.
8. Malignancy within the past 5 years, with the exception of in situ removal of basal cell carcinoma.
9. Any planned major surgery within the duration of the trial.
10. Patients who are pregnant, currently breastfeeding, or intend to become pregnant during the course of the trial.
11. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibodies and/or human immunodeficiency virus (HIV).
12. After 10 minutes supine rest at the time of screening, any vital signs outside the following ranges:
* Systolic blood pressure (BP): \<90 or \>160 mmHg, or
* Diastolic blood pressure \<50 or \>95 mmHg, or
* Pulse \<40 or \>90 bpm
13. Prolonged QTcF (\> 450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the Investigator.
14. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to SYN321, including disinfectants and adhesives or hypersensitivity to acetylsalicylic acid.
15. History of asthma, angioedema, urticaria or acute rhinitis induced by NSAID, including acetylsalicylic acid.
16. Regular use of any prescribed or non-prescribed medications, including but not limited to antacids, analgesics, herbal remedies, vitamins and minerals, within 10 days prior to the first administration of IMP, as well as nasal decongestants without cortisone, antihistamine, or anticholinergics for a maximum of 10 days, at the discretion of the Investigator.
17. Patient has taken pain medication or has received pain medicine other than paracetamol for conditions unrelated to KOA of the index knee within 10 days prior to the injection.
18. Planned treatment or treatment with another investigational drug within 3 months prior to Day 1. Patients consented and screened but not dosed in previous phase 1 studies will not be excluded.
19. Current smokers or users of nicotine products. Irregular use of nicotine (e.g., smoking, snuffing, chewing tobacco) less than 3 times/week before the screening visit will be allowed.
20. Positive screen for drugs of abuse or alcohol at screening. Positive results that are expected given the patient's medical history and prescribed medications can be disregarded as judged by the Investigator.
21. History of or current alcohol abuse or excessive intake of alcohol, as judged by the Investigator.
22. History of or current drug abuse, as judged by the Investigator.
23. History of or current use of anabolic steroids, as judged by the Investigator.
24. Plasma donation within 1 month of screening or blood donation (or corresponding blood loss) during the last 3 months prior to screening.
25. The Investigator considers the patient unlikely to comply with trial procedures, restrictions, and requirements.
Minimum Eligible Age
40 Years
Maximum Eligible Age
79 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CTC Clinical Trial Consultants AB
INDUSTRY
Sponsor Role
collaborator
Synartro AB
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cinical Trial Consultants AB
Uppsala, , Sweden
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Sweden
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-517920-21-00
Identifier Type: CTIS
Identifier Source: secondary_id
SYN321-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study of Safety and Efficacy of 6 mL Synvisc-One (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial and Repeat Treatment
NCT02389452
COMPLETED
PHASE4
Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)
NCT02095548
COMPLETED
PHASE1
A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain
NCT03660943
COMPLETED
PHASE3
A Study to Evaluate the Efficacy, Safety and Tolerability of EVI-01 Intra-Articular Injection in Osteoarthritis of the Knee
NCT05337540
COMPLETED
NA
Durolane Versus Methylprednisolone in Knee Osteoarthritis
NCT01209364
COMPLETED
PHASE3
A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
NCT02536833
COMPLETED
PHASE2
A Study of MEDI7352 in Painful Osteoarthritis of the Knee
NCT02508155
COMPLETED
PHASE1
An Efficacy and Safety Study of Two Doses of Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee
NCT01839331
COMPLETED
PHASE2
Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
NCT03727022
COMPLETED
PHASE2
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
NCT07225829
RECRUITING
PHASE2
Pivotal Study to Evaluate Efficacy and Safety of SP5M002 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis
NCT06399042
ACTIVE_NOT_RECRUITING
PHASE3
Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)
NCT03583346
COMPLETED
PHASE1
A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis
NCT03133676
COMPLETED
PHASE1
Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part I
NCT01463488
COMPLETED
PHASE1
First-in-human, Safety, Tolerability and Pharmacokinetics Study of LRX712 in Osteoarthritic Patients
NCT03355196
COMPLETED
PHASE1
Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.
NCT03275064
COMPLETED
PHASE2
Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA
NCT04097379
COMPLETED
PHASE2
A Randomized, Controlled Study to Evaluate Efficacy and Safety of Intra-articular Ampion for Osteoarthritis Pain in Knee
NCT02024529
COMPLETED
PHASE3
A Study of the Efficacy and Safety of MEDI7352 in Participants With Painful Osteoarthritis of the Knee
NCT04675034
COMPLETED
PHASE2
A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS
NCT01091116
COMPLETED
PHASE2
An Effectiveness and Safety 6 Months Study of 3 Injections One Week Apart of SYNOLIS VA 40/80 in the Treatment of Symptomatic Knee Osteoarthritis
NCT05829850
COMPLETED
NA
A Study Utilizing Patient-Reported and Radiographic Outcomes and Evaluating the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
NCT03928184
COMPLETED
PHASE3
A Trial of SB-061 in Osteoarthritis of the Knee
NCT02802709
COMPLETED
PHASE1/PHASE2
Intra-articular Injections for Knee Osteoarthritis: A Single Blinded Prospective Randomized Trial
NCT02995083
WITHDRAWN
EARLY_PHASE1